- Home
- ETWO vs COGT Comparison
ETWO vs COGT Comparison
Compare ETWO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETWO
- COGT
- Stock Information
- Founded
- ETWO 2000
- COGT 2014
- Country
- ETWO United States
- COGT United States
- Employees
- ETWO N/A
- COGT N/A
- Industry
- ETWO EDP Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- ETWO Technology
- COGT Health Care
- Exchange
- ETWO Nasdaq
- COGT Nasdaq
- Market Cap
- ETWO 1.3B
- COGT 1.1B
- IPO Year
- ETWO N/A
- COGT 2018
- Fundamental
- Price
- ETWO $3.16
- COGT $10.02
- Analyst Decision
- ETWO Hold
- COGT Buy
- Analyst Count
- ETWO 3
- COGT 6
- Target Price
- ETWO $3.90
- COGT $14.33
- AVG Volume (30 Days)
- ETWO 1.9M
- COGT 1.2M
- Earning Date
- ETWO 01-07-2025
- COGT 11-12-2024
- Dividend Yield
- ETWO N/A
- COGT N/A
- EPS Growth
- ETWO N/A
- COGT N/A
- EPS
- ETWO N/A
- COGT N/A
- Revenue
- ETWO $619,301,000.00
- COGT N/A
- Revenue This Year
- ETWO N/A
- COGT N/A
- Revenue Next Year
- ETWO $3.01
- COGT N/A
- P/E Ratio
- ETWO N/A
- COGT N/A
- Revenue Growth
- ETWO N/A
- COGT N/A
- 52 Week Low
- ETWO $2.93
- COGT $3.67
- 52 Week High
- ETWO $5.08
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- ETWO 42.46
- COGT 39.86
- Support Level
- ETWO $2.93
- COGT $9.97
- Resistance Level
- ETWO $3.45
- COGT $11.16
- Average True Range (ATR)
- ETWO 0.12
- COGT 0.72
- MACD
- ETWO 0.05
- COGT -0.16
- Stochastic Oscillator
- ETWO 43.81
- COGT 28.48
About ETWO E2open Parent Holdings Inc.Class A
E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.